140 related articles for article (PubMed ID: 20216404)
1. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.
Sakr RA; Barbashina V; Morrogh M; Chandarlapaty S; Andrade VP; Arroyo CD; Olvera N; King TA
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):371-4. PubMed ID: 20216404
[TBL] [Abstract][Full Text] [Related]
2. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
Garg K; Broaddus RR; Soslow RA; Urbauer DL; Levine DA; Djordjevic B
Int J Gynecol Pathol; 2012 Jan; 31(1):48-56. PubMed ID: 22123723
[TBL] [Abstract][Full Text] [Related]
3. A robust immunohistochemical assay for detecting PTEN expression in human tumors.
Sangale Z; Prass C; Carlson A; Tikishvili E; Degrado J; Lanchbury J; Stone S
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):173-83. PubMed ID: 20930614
[TBL] [Abstract][Full Text] [Related]
4. Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry.
Schläfli AM; Berezowska S; Adams O; Langer R; Tschan MP
Eur J Histochem; 2015 May; 59(2):2481. PubMed ID: 26150155
[TBL] [Abstract][Full Text] [Related]
5. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
6. PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
Tekesin K; Emin Gunes M; Bayrak S; Akar E; Ozturk T; Altinay S; Tural D
J BUON; 2019; 24(5):1920-1926. PubMed ID: 31786856
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
8. A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.
Jensen K; Krusenstjerna-Hafstrøm R; Lohse J; Petersen KH; Derand H
Mod Pathol; 2017 Feb; 30(2):180-193. PubMed ID: 27767098
[TBL] [Abstract][Full Text] [Related]
9. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.
Lotan TL; Gurel B; Sutcliffe S; Esopi D; Liu W; Xu J; Hicks JL; Park BH; Humphreys E; Partin AW; Han M; Netto GJ; Isaacs WB; De Marzo AM
Clin Cancer Res; 2011 Oct; 17(20):6563-73. PubMed ID: 21878536
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of methods for preserving PTEN antigenicity in stored paraffin sections.
Gelb AB; Freeman VA; Astrow SH
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):569-73. PubMed ID: 21552118
[TBL] [Abstract][Full Text] [Related]
11. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
Fujita T; Doihara H; Kawasaki K; Takabatake D; Takahashi H; Washio K; Tsukuda K; Ogasawara Y; Shimizu N
Br J Cancer; 2006 Jan; 94(2):247-52. PubMed ID: 16404430
[TBL] [Abstract][Full Text] [Related]
12. Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples.
Pu T; Guo P; Qiu Y; Chen S; Yang L; Sun L; Ye F; Bu H
Int J Clin Exp Pathol; 2015; 8(9):10565-74. PubMed ID: 26617766
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
[TBL] [Abstract][Full Text] [Related]
14. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
[TBL] [Abstract][Full Text] [Related]
15. Automated Extraction of Formalin-Fixed, Paraffin-Embedded Tissue for High-Risk Human Papillomavirus Testing of Head and Neck Squamous Cell Carcinomas Using the Roche Cobas 4800 System.
Kerr DA; Sweeney B; Arpin RN; Ring M; Pitman MB; Wilbur DC; Faquin WC
Arch Pathol Lab Med; 2016 Aug; 140(8):844-8. PubMed ID: 27031775
[TBL] [Abstract][Full Text] [Related]
16. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
18. Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues.
Steiner C; Tille JC; Lamerz J; Kux van Geijtenbeek S; McKee TA; Venturi M; Rubbia-Brandt L; Hochstrasser D; Cutler P; Lescuyer P; Ducret A
Mol Cell Proteomics; 2015 Oct; 14(10):2786-99. PubMed ID: 26149442
[TBL] [Abstract][Full Text] [Related]
19. Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues.
Sorrelle N; Ganguly D; Dominguez ATA; Zhang Y; Huang H; Dahal LN; Burton N; Ziemys A; Brekken RA
J Immunol; 2019 Jan; 202(1):292-299. PubMed ID: 30510069
[TBL] [Abstract][Full Text] [Related]
20. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
